# evERA (NCT05306340)

> A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

No report yet. It can be ordered.

- Drugs tested: giredestrant plus everolimus
- Indication: ER-positive HER2-negative locally advanced or metastatic breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05306340
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Genentech, Inc.
- Conditions: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Interventions: Giredestrant; Exemestane; Fulvestrant; Tamoxifen; Everolimus; LHRH Agonist; Dexamethasone Mouth Rinse
- Enrollment: 373
- Primary outcome: Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population

## Indexed commentary on evERA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 139
- YouTube: 30
- Podcasts: 13
- X videos: 6
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=evera-nct05306340

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05306340", "email": "<work email>"}; the inbox owner confirms by the emailed link.